Evidence map›Paper›PMID 36426376›Full record

ArticleJHEP reports : innovation in hepatology2022

Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study.

Thijmen Visseren, Nicole S Erler, Julie K Heimbach, John E Eaton, Nazia Selzner, Aliya Gulamhusein, Frans van der Heide, Robert J Porte, Bart van Hoek, Ian P J Alwayn and 3 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Review
  5. Article
  6. Review
  7. Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
    Article
  8. Article
  9. Primary sclerosing cholangitis.Nature reviews. Disease primers · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Gut · 2024
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Thijmen VisserenErasmus MC Transplant Institute, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Nicole S ErlerDepartment of Biostatistics, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Julie K HeimbachDepartment of Surgery, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
John E EatonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Nazia SelznerMultiorgan Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
Aliya GulamhuseinMultiorgan Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
Frans van der HeideDepartment of Gastroenterology and Hepatology, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands.
Robert J PorteHPB and Liver Transplant Surgery, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands.
Bart van HoekLUMC Transplant Center, Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Ian P J AlwaynDepartment of General Surgery, Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada.
Herold J MetselaarErasmus MC Transplant Institute, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jan N M IJzermansErasmus MC Transplant Institute, Department of Surgery, Division of Hepatopancreaticobiliary and Transplant Surgery, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Sarwa Darwish MuradErasmus MC Transplant Institute, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Erasmus MC · NLUniversity Health Network · CADalhousie University · CALeiden University Medical Center · NLMayo Clinic · USUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Liver transplantation (LT) for primary sclerosing cholangitis (PSC) is complicated by recurrence of PSC (rPSC) in up to 25% of recipients. Recurrence has been shown to be detrimental for both graft and patient survival. For both PSC and rPSC, a medical cure is not available. To predict and ideally to prevent rPSC, it is imperative to find risk factors for rPSC that can be potentially modified. Therefore, we aimed to identify such factors for rPSC in a large international multicentre study including 6 centres in PSC-prevalent countries. Methods: In this international multicentre, retrospective cohort study, 531 patients who underwent transplantation for PSC were included. In 25% of cases (n = 131), rPSC was diagnosed after a median follow-up of 6.72 (3.29-10.11) years post-LT. Results: In the multivariable competing risk model with time-dependent covariates, we found that factors representing an increased inflammatory state increase the risk for rPSC. Recurrent cholangitis before LT as indication for LT (hazard ratio [HR] 3.6, 95% CI 2.5-5.2), increased activity of inflammatory bowel disease after LT (HR 1.7, 95% CI 1.08-2.75), and multiple acute cellular rejections (HR: non-linear) were significantly and independently associated with an increased risk of rPSC. In contrast to the findings of previous studies, pretransplant colectomy was not found to be independently protective against the development of rPSC. Conclusions: An increased inflammatory state before and after LT may play a causal and modifiable role in the development of rPSC. Pretransplant colectomy did not reduce the risk of rPSC Impact and implications: Recurrence of PSC (rPSC) negatively affects survival after liver transplant (LT). Modifiable risk factors could guide clinical management and prevention of rPSC. We demonstrate that an increased inflammatory state both before and after LT increases the incidence of rPSC. As these are modifiable factors, they could serve as targets for future studies and therapies. We also added further evidence to the ongoing debate regarding preventive colectomy for rPSC by reporting that in our multicenter study, we could not find an independent association between colectomy and risk of rPSC.

Indexed as

ACR, acute cellular rejectionCCA, cholangiocarcinomaCD, Crohn's diseaseCholestatic liver diseaseColectomyDBD, donation after brain deathDCD, donation after cardiac deathELTR, European Liver Transplant RegistryHR, hazard ratioIBD, inflammatory bowel diseaseIBD-U, inflammatory bowel disease–unclassifiedInflammatory bowel diseaseLD, living donorLiver transplantationLT, liver transplantationMELD, model for end-stage liver diseaseMRI, magnetic resonance imagingPrimary sclerosing cholangitisPSC, primary sclerosing cholangitisRecurrence of diseaseRisk factorsrPSC, recurrence of primary sclerosing cholangitisSES-CD, Simple Endoscopic Score for Crohn's DiseaseUC, ulcerative colitis

Identifiers

PMID36426376
PMCPMC9678780
OpenAlexW4298625046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.